American Society of Hematology

Figure 2

$The PKCβ inhibitor enzastaurin efficiently kills human CLL cells in vitro independent of risk factor mutation status or CD38. Human CLL cells were cultured in vitro, as described in Document S1. Indicated concentrations of enzastaurin were added, and the viable cell fraction was determined as the annexin V–negative population by flow cytometry, compared with controls. Results after 24 hours of treatment are shown. Table S1 shows the patient characteristics. (A) Data for 9 mutated (MUT) and 8 unmutated (UMT) CLL samples are shown as mean plus or minus SE. (B) Data for 10 CD38 high-risk and 7 CD38 low-risk patients are shown. (C) Survival of T cells from the same samples is shown as mean plus or minus SEM.$

The PKCβ inhibitor enzastaurin efficiently kills human CLL cells in vitro independent of risk factor mutation status or CD38. Human CLL cells were cultured in vitro, as described in Document S1. Indicated concentrations of enzastaurin were added, and the viable cell fraction was determined as the annexin V–negative population by flow cytometry, compared with controls. Results after 24 hours of treatment are shown. Table S1 shows the patient characteristics. (A) Data for 9 mutated (MUT) and 8 unmutated (UMT) CLL samples are shown as mean plus or minus SE. (B) Data for 10 CD38 high-risk and 7 CD38 low-risk patients are shown. (C) Survival of T cells from the same samples is shown as mean plus or minus SEM.

This Feature Is Available To Subscribers Only